Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B streptococci from lungs of infected mice

Infection and Immunity

Volumn 70, Issue 11, 2002, Pages 6409-6415

  Cheng, Qi ^a   Debol, Steven ^a   Lam, Hong ^a   Eby, Ron ^a   Edwards, Lorri ^a   Matsuka, Yury ^a   Olmsted, Stephen B ^a   Cleary, Patrick ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL ANTIGEN; MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE; STREPTOCOCCAL C5A PEPTIDASE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LUNG CLEARANCE; LUNG INFECTION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS AGALACTIAE;

ADHESINS, BACTERIAL; ANIMALS; BLOOD BACTERICIDAL ACTIVITY; ENDOPEPTIDASES; FEMALE; IMMUNIZATION; LUNG; MICE; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE;

EID: 0036841265     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.11.6409-6415.2002     Document Type: Article

References (38)

1. Ablow, R. C., S. G. Driscoll, E. L. Effmann, I. Gross, C. J. Jolles, R. Uauy, and J. B. Warshaw. 1976. A comparison of early-onset group B streptococcal neonatal infection and the respiratory-distress syndrome of the newborn. N. Engl. J. Med. 294:65-70.
2. Baker, C. J., and M. S. Edwards. 1995. Group B streptococcal infections, p. 980-1054. In J. S. Remington and J. O. Klein (ed.), Infectious diseases of the fetus and newborn infant, 4th ed. W. B. Saunders Co., Philadelphia, Pa.
3. Baker, C. J., N. A. Halsey, and A. Schuchat. 1999. 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. Pediatrics 103:197-198.
4. Baker, C. J., and D. L. Kasper. 1976. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294:753-756.
5. Baker, C. J., and D. L. Kasper. 1985. Group B streptococcal vaccines. Rev. Infect. Dis. 7:458-467.
6. Baker, C. J., L. C. Paoletti, M. R. Wessels, H. K. Guttormsen, M. A. Rench, M. E. Hickman, and D. L. Kasper. 1999. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J. Infect. Dis. 179:142-150.
7. Beckmann, C., J. D. Waggoner, T. O. Harris, G. S. Tamura, and C. E. Rubens. 2002. Identification of novel adhesins from group B streptococci by use of phage display reveals that Csa peptidase mediates fibronectin binding. Infect. Immun. 70:2869-2876.
8. Bohnsack, J. F., K. Widjaja, S. Ghazizadeh, C. E. Rubens, D. R. Hillyard, C. J. Parker, K. H. Albertine, and H. R. Hill. 1997. A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections. J. Infect. Dis. 175:847-855.
9. Bohnsack, J. F., J. Chang, and H. R. Hill. 1993. Restricted ability of group B streptococcal C5a prepared from different animal species. Infect. Immun. 61:1421-1426.
10. Bohnsack, J. F., K. W. Mollison, A. M. Buko, J. C. Ashworth, and H. R. Hill. 1991. Group B streptococci inactivate C5a by enzymatic cleavage at the carboxy terminus. Biochem. J. 273:635-640.
11. Bohnsack, J. F., S. Takahashi, L. Hammitt, D. V. Miller, A. A. Aly, and E. E. Adderson. 2000. Genetic polymorphisms of group B streptococcus SCPB alter functional activity of a cell-associated peptidase that inactivates C5a. Infect. Immun. 68:5018-5025.
12. Cheng, Q., B. Carlson, S. Pillai, R. Eby, L. Edwards, S. B. Olmsted, and P. Cleary. 2001. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect. Immun. 69:2302-2308.
13. Cheng, Q., D. Stafslien, S. S. Purushothaman, and P. Cleary. 2002. The group B streptococcal C5a peptidase is both a specific protease and an invasin. Infect. Immun. 70:2408-2413.
14. Chmouryguina, I., A. Suvorov, P. Ferrieri, and P. P. Cleary. 1996. Conservation of the C5a peptidase genes in group A and B streptococci. Infect. Immun. 64:2387-2390.
15. Deng, L., D. L. Kasper, T. P. Krick, and M. R. Wessels. 2000. Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus. J. Biol. Chem. 275:7497-7504.
16. Gibson, R. L., C. Soderland, W. R. Henderson, Jr., E. Y. Chi, and C. E. Rubens. 1995. Group B streptococci (GBS) injure lung endothelium in vitro: GBS invasion and GBS-induced eicosanoid production is greater with microvascular than with pulmonary artery cells. Infect. Immun. 63:271-279.
17. Gravekamp, C., D. L. Kasper, L. C. Paoletti, and L. C. Madoff. 1999. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect. Immun. 67:2491-2496.
18. Harrison, L. H., J. A. Elliott, D. M. Dwyer, J. P. Libonati, P. Ferrieri, L. Billmann, and A. Schuchat. 1998. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J. Infect. Dis. 177:998-1002.
19. Hill, H. R., J. F. Bohnsack, E. Z. Morris, N. H. Augustine, C. J. Parker, P. P. Cleary, and J. T. Wu. 1988. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J. Immunol. 141:3551-3556.
20. Hordnes, K., T. Tynning, A. I. Kvam, R. Jonsson, and B. Haneberg. 1996. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect. Immun. 64:1643-1652.
21. Ji, Y., L. McLandsborough, A. Kondagunta, and P. P. Cleary. 1996. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect. Immun. 64:503-510.
22. Ji, Y., N. Schnitzler, D. DeMaster, and P. P. Cleary. 1998. Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect. Immun. 66:5399-5405.
23. Katzenstein, A. L., C. Davis, and A. Braude. 1976. Pulmonary changes in neonatal sepsis to group B beta-hemolytic Streptococcus: relation of hyaline membrane disease. J. Infect. Dis. 133:430-435.
24. Kauppi, M., L. Saarinen, and H. Kayhty. 1993. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J. Infect. Dis. 167:365-371.
25. Lancefield, R. C. 1962. Current knowledge of the type specific M antigens of group A streptococci. J. Immunol. 89:307-313.
26. Larsson, C., M. Stalhammar-Carlemalm, and G. Lindahl. 1996. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and α. Infect. Immun. 64:3518-3523.
27. Larsson, C., M. Stalhammar-Carlemalm, and G. Lindahl. 1999. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine 17:454-458.
28. Lin, F. Y., J. D. Clements, P. H. Azimi, J. A. Regan, L. E. Weisman, J. B. Philips III, G. G. Rhoads, P. Clark, R. A. Brenner, and P. Ferrieri. 1998. Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J. Infect. Dis. 177:790-792.
29. Madoff, L. C., L. C. Paoletti, J. Y. Tai, and D. L. Kasper. 1994. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J. Clin. Investig. 94:286-292.
30. Nizet, V., R. L. Gibson, E. Y. Chi, P. E. Framson, M. Hulse, and C. E. Rubens. 1996. Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect. Immun. 64:3818-3826.
31. Shen, X., T. Lagergard, Y. Yang, M. Lindblad, M. Fredriksson, and J. Holmgren. 2000. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19:850-861.
32. Stafslien, D. K., and P. P. Cleary. 2000. Characterization of the streptococcal C5a peptidase using a C5a-green fluorescent protein fusion protein substrate. J. Bacteriol. 182:3254-3258.
33. Suvorov, A. N., P. P. Cleary, and P. Ferrieri. 1991. C5a peptidase gene from group B streptococci, p. 230-232. In G. Dunny, P. P. Cleary, and L. McKay (ed.), Genetics and molecular biology of streptococci, lactococci, and enterococci. American Society for Microbiology, Washington, D.C.
34. Valentin-Weigand, P., and G. S. Chhatwal. 1995. Correlation of epithelial cell invasiveness of group B streptococci with clinical source of isolation. Microb. Pathog. 19:83-91.
35. von Hunolstein, C., S. D'Ascenzi, B. Wagner, J. Jelinkova, G. Alfarone, S. Recchia, M. Wagner, and G. Orefici. 1993. Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci). Infect. Immun. 61:1272-1280.
36. Wennerstrom, D. E., and R. W. Schutt. 1978. Adult mice as a model for early onset group B streptococcal disease. Infect. Immun. 19:741-744.
37. Wessels, M. R., L. C. Paoletti, D. L. Kasper, J. L. DiFabio, F. Michon, K. Holme, and H. J. Jennings. 1990. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Investig. 86:1428-1433.
38. Wexler, D., E. D. Chenoweth, and P. Cleary. 1985. A streptococcal inactivator of chemotaxis: a new virulence factor specific to group A streptococci. Proc. Natl. Acad. Sci. USA 82:179-180.